ClinicalTrials.gg
CompletedNCT02482298Hestia2Updated Dec 19, 2018Results posted

A Study to Assess the Effect of Ticagrelor in Reducing the Number of Days With Pain in Patients With Sickle Cell Disease

A Phase 2 interventional study of Ticagrelor and Placebo in Sickle Cell Disease, sponsored by AstraZeneca. Completed at 20 sites in 8 countries. Open to participants aged 18 Years to 30 Years. Per ClinicalTrials.gov, last updated 2018-12-19.

Sponsored by AstraZeneca · Phase 2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
87
Allocation
Randomized
Ages
18 Years to 30 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 733 studies in Anemia, Sickle Cell with a site in United States — 134 open to participants now, 185 under way, 16 of them phase 3. Anemia, Sickle Cell · United States.

Enrollment
127th of 559
87 · median 31
Started
2015
with 37 others
Phase 2
161 of 733
23 open now
Registered
313th of 733
by date

Among the 733 studies in Anemia, Sickle Cell with a site in United States, this one is the 127th largest by enrollment of the 559 interventional ones that give a count, is one of 38 that started in 2015, is one of 161 in phase 2, and was the 313th registered.

Anemia, Sickle Cell

1,134 studies on the registry are indexed under Anemia, Sickle Cell; 238 are open to participants now.

Browse Anemia, Sickle Cell studies →

Open to participants now

134 of the 733 studies in Anemia, Sickle Cell with a site in United States are open now. Recruiting first, the newest first:

129 more — sign in →

All 134 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 177 Anemia, Sickle Cell studies recruiting now, 64 (36%) set no upper age limit and 97 (55%) stop at 75 or younger; 127 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 30 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 733 studies in Anemia, Sickle Cell with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether ticagrelor is effective in reducing the number of days of pain, intensity of pain, and reducing the use of analgesics due to sickle cell disease

Read the detailed description

This is a randomised, double-blind, double-dummy, parallel-group, placebo-controlled, study evaluating 2 doses of ticagrelor in 90 patients aged 18 to 30 years, with sickle cell disease (SCD). Patients will be randomised to double-blind double-dummy treatment period in a 1:1:1 ratio (30 to each treatment group) to receive ticagrelor 10 mg twice daily (bid), or ticagrelor 45 mg bid, or placebo bid to determine the frequency of days with pain using an electronic diary (eDiary) every day. Approximately 180 patients will be enrolled. Patient will be followed for safety assessment during and after 2 weeks of treatment completion.

During the 16 week treatment period, patients will complete a daily eDiary concerning daily pain intensity, pain location, use of analgesics and absence from school or work. At the end of the study patients will be asked to rate the change in their sickle cell pain compared to the start of treatment. Platelet aggregation will be measured and reported as P2Y12 reaction units (PRU) pre-dose and 2 hours post-dose at week 4 and week 5 after treatment start. Pharmacokinetic (PK) parameters will be measured at 2 hours post-dose at week 4, and pre-dose and at 2 hours post-dose at week 5. Biomarkers will be assessed pre-dose at week 4, week 5 and week 8. During the study, patients will be evaluated for adverse events (AEs) including bleeding and vaso-occlusive crisis (VOC).

03

Conditions studied

  • Sickle Cell Disease

Browse trials for

Keywords

  • Sickle cell disease
  • Young adults
  • Hestia2
  • Ticagrelor
04

Who can participate

Ages eligible
18 Years to 30 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed medical history or diagnosis of homozygous sickle cell (HbSS) or sickle beta-zero-thalassaemia (HbS/β0) by HPLC
  • If treated with hydroxyurea, the dose must have been stable for 3 months

Exclusion criteria

Exclusion Criteria:

  • History of or clinically overt cerebrovascular accident
  • Moderate or severe hepatic impairment
  • Treatment with chronic red blood cell transfusion therapy
  • Pre-dominate cause of pain is not sickle cell disease related
  • Chronic treatment with anticoagulants or antiplatelet drugs.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
87 participants (actual)

Study arms

  • Experimental
    Dose A

    Drug: Ticagrelor

  • Experimental
    Dose B

    Drug: Ticagrelor

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Two arms: 1) 10 mg ticagrelor + 45 mg ticagrelor placebo or 2) 45 mg ticagrelor + 10 mg ticagrelor placebo. Drugs taken orally, twice a day (morning and evening, at least 12 hours apart) from randomization until the end of treatment.

  • DrugPlacebo

    10 mg ticagrelor placebo + 45 mg ticagrelor placebo. Drugs taken orally, twice a day (morning and evening at least 12 hours apart) from randomization until the end of treatment

06

What researchers measure

Primary outcomes

  1. Change in Proportion of Days With Pain Due to Sickle Cell Disease as Measured by an eDiary

    To investigate the efficacy of 2 different doses of ticagrelor versus placebo in reducing the number of days with pain due to sickle cell disease.

    Time frame: Baseline through Week 12

Secondary outcomes

  1. Average of the Daily Worst Pain Values Reported Via eDiary

    To determine the efficacy of 2 different doses of ticagrelor versus placebo in reducing the intensity of pain due to sickle cell disease. Intensity of pain was recorded on an 11-point scale where 0 represented no pain and 10 represented the worst pain imaginable.

    Time frame: Baseline through Week 12

  2. Change in Proportion of Days With Analgesic Use Measured by an eDiary

    To assess the efficacy of 2 different doses of ticagrelor versus placebo in reducing the use of analgesics by patients with sickle cell disease.

    Time frame: Baseline through Week 12

Other outcomes

  1. Number of Major Bleeding or Clinically Relevant Non-major Bleeding Events (Patients)

    To assess safety and tolerability of 2 different doses of ticagrelor versus placebo in patients with SCD

    Time frame: Baseline through Week 12

  2. Number of Major Bleeding or Clinically Relevant Non-major Bleeding Events (Events)

    To assess safety and tolerability of 2 different doses of ticagrelor versus placebo in patients with SCD

    Time frame: Baseline through Week 12

07

Results

Posted Dec 14, 2017

Participant flow

This study was conducted at 26 centers in 8 countries between 09 July 2015 and 16 November 2016.

Participant flow — Overall Study
MilestonePLACEBO 10MG BID + PLACEBO 45MG BIDTICAGRELOR 10MG BID + PLACEBO 45MG BIDTICAGRELOR 45MG BID + PLACEBO 10MG BID
Started302730
Completed282427
Not completed233
Withdrew: Withdrawal by subject212
Withdrew: Did not fulfill randomization criteria010
Withdrew: Dev. of study-spec. withdrawal criteria001
Withdrew: Lost to follow-up010

Outcome measures

PrimaryChange in Proportion of Days With Pain Due to Sickle Cell Disease as Measured by an eDiary

To investigate the efficacy of 2 different doses of ticagrelor versus placebo in reducing the number of days with pain due to sickle cell disease.

Time frame:
Baseline through Week 12
Reported as:
Least squares mean · Proportion of days with pain
Change in Proportion of Days With Pain Due to Sickle Cell Disease as Measured by an eDiary
Proportion of days with painPLACEBO 10MG BID + PLACEBO 45MG BIDTICAGRELOR 10MG BID + PLACEBO 45MG BIDTICAGRELOR 45MG BID + PLACEBO 10MG BID
Change in Proportion of Days With Pain Due to Sickle Cell Disease as Measured by an eDiary-0.1802 ± 0.05453-0.1352 ± 0.05287-0.1001 ± 0.05233
Statistical analysis
  • PLACEBO 10MG BID + PLACEBO 45MG BID vs TICAGRELOR 10MG BID + PLACEBO 45MG BID · Mixed Models Analysis · Mean difference (final values): 0.0450 · 90% CI -0.0610 to 0.1510
  • PLACEBO 10MG BID + PLACEBO 45MG BID vs TICAGRELOR 45MG BID + PLACEBO 10MG BID · Mixed Models Analysis · Mean difference (final values): 0.0801 · 90% CI -0.0230 to 0.1832
SecondaryAverage of the Daily Worst Pain Values Reported Via eDiary

To determine the efficacy of 2 different doses of ticagrelor versus placebo in reducing the intensity of pain due to sickle cell disease. Intensity of pain was recorded on an 11-point scale where 0 represented no pain and 10 represented the worst pain imaginable.

Time frame:
Baseline through Week 12
Reported as:
Mean · Average daily worst pain rating
Average of the Daily Worst Pain Values Reported Via eDiary
Average daily worst pain ratingPLACEBO 10MG BID + PLACEBO 45MG BIDTICAGRELOR 10MG BID + PLACEBO 45MG BIDTICAGRELOR 45MG BID + PLACEBO 10MG BID
Average of the Daily Worst Pain Values Reported Via eDiary1.02 ± 1.1061.15 ± 1.5471.74 ± 2.277
SecondaryChange in Proportion of Days With Analgesic Use Measured by an eDiary

To assess the efficacy of 2 different doses of ticagrelor versus placebo in reducing the use of analgesics by patients with sickle cell disease.

Time frame:
Baseline through Week 12
Reported as:
Least squares mean · Proportion of days with analgesic use
Change in Proportion of Days With Analgesic Use Measured by an eDiary
Proportion of days with analgesic usePLACEBO 10MG BID + PLACEBO 45MG BIDTICAGRELOR 10MG BID + PLACEBO 45MG BIDTICAGRELOR 45MG BID + PLACEBO 10MG BID
Change in Proportion of Days With Analgesic Use Measured by an eDiary-0.1991 ± 0.08763-0.0799 ± 0.08540-0.1016 ± 0.08664
Statistical analysis
  • PLACEBO 10MG BID + PLACEBO 45MG BID vs TICAGRELOR 10MG BID + PLACEBO 45MG BID · Mixed Models Analysis · Mean difference (final values): 0.1192 · 90% CI 0.0350 to 0.2035
  • PLACEBO 10MG BID + PLACEBO 45MG BID vs TICAGRELOR 45MG BID + PLACEBO 10MG BID · Mixed Models Analysis · Mean difference (final values): 0.0975 · 90% CI 0.0155 to 0.1795
Other pre-specifiedNumber of Major Bleeding or Clinically Relevant Non-major Bleeding Events (Patients)

To assess safety and tolerability of 2 different doses of ticagrelor versus placebo in patients with SCD

Time frame:
Baseline through Week 12
Reported as:
Number · Number of patients
Number of Major Bleeding or Clinically Relevant Non-major Bleeding Events (Patients)
Number of patientsPLACEBO 10MG BID + PLACEBO 45MG BIDTICAGRELOR 10MG BID + PLACEBO 45MG BIDTICAGRELOR 45MG BID + PLACEBO 10MG BID
Patients with any bleeding events222
Pts w/ any bleeding event requiring intervention212
Other pre-specifiedNumber of Major Bleeding or Clinically Relevant Non-major Bleeding Events (Events)

To assess safety and tolerability of 2 different doses of ticagrelor versus placebo in patients with SCD

Time frame:
Baseline through Week 12
Reported as:
Number · Number of events
Number of Major Bleeding or Clinically Relevant Non-major Bleeding Events (Events)
Number of eventsPLACEBO 10MG BID + PLACEBO 45MG BIDTICAGRELOR 10MG BID + PLACEBO 45MG BIDTICAGRELOR 45MG BID + PLACEBO 10MG BID
Total number of bleeding events222
Maximum severity of bleeding event: Minor010
Max sever. of bleed event: Clin-relevant nonmajor212
Maximum severity of bleeding event: Major000

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
PLACEBO 10MG BID + PLACEBO 45MG BID—6/30 (20%)16/30 (53.3%)
TICAGRELOR 10MG BID + PLACEBO 45MG BID—6/26 (23.1%)15/26 (57.7%)
TICAGRELOR 45MG BID + PLACEBO 10MG BID—5/30 (16.7%)20/30 (66.7%)
Most frequent serious events
Showing 10 of 14
Most frequent serious events
EventPLACEBO 10MG BID + PLACEBO 45MG BIDTICAGRELOR 10MG BID + PLACEBO 45MG BIDTICAGRELOR 45MG BID + PLACEBO 10MG BID
Sickle cell anaemia with crisisBlood and lymphatic system disorders3/305/263/30
GastroenteritisInfections and infestations2/300/261/30
Lower respiratory tract infectionInfections and infestations0/301/260/30
ArthralgiaMusculoskeletal and connective tissue disorders0/301/260/30
HeadacheNervous system disorders0/301/260/30
Acute chest syndromeRespiratory, thoracic and mediastinal disorders0/301/261/30
ReticulocytopeniaBlood and lymphatic system disorders0/300/261/30
Local swellingGeneral disorders1/300/260/30
Hepatic ischaemiaHepatobiliary disorders1/300/260/30
CellulitisInfections and infestations1/300/260/30
Most frequent other events
Showing 10 of 21
Most frequent other events
EventPLACEBO 10MG BID + PLACEBO 45MG BIDTICAGRELOR 10MG BID + PLACEBO 45MG BIDTICAGRELOR 45MG BID + PLACEBO 10MG BID
HeadacheNervous system disorders8/3011/268/30
ArthralgiaMusculoskeletal and connective tissue disorders6/306/269/30
Pain in extremityMusculoskeletal and connective tissue disorders5/304/269/30
Back painMusculoskeletal and connective tissue disorders7/304/264/30
Abdominal painGastrointestinal disorders3/305/263/30
Non-cardiac chest painGeneral disorders3/303/264/30
PneumoniaInfections and infestations2/302/264/30
Upper respiratory tract infectionInfections and infestations4/301/261/30
Urinary tract infectionInfections and infestations4/302/262/30
Musculoskeletal painMusculoskeletal and connective tissue disorders2/303/263/30

Baseline characteristics

Age, Continuous
Age, Continuous(Years)PLACEBO 10MG BID + PLACEBO 45MG BIDTICAGRELOR 10MG BID + PLACEBO 45MG BIDTICAGRELOR 45MG BID + PLACEBO 10MG BIDTotal
Mean21.6 ± 3.4221.9 ± 2.7223.2 ± 3.6922.2 ± 3.35
Sex: Female, Male
Sex: Female, Male(Participants)PLACEBO 10MG BID + PLACEBO 45MG BIDTICAGRELOR 10MG BID + PLACEBO 45MG BIDTICAGRELOR 45MG BID + PLACEBO 10MG BIDTotal
Female16151647
Male14121440
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PLACEBO 10MG BID + PLACEBO 45MG BIDTICAGRELOR 10MG BID + PLACEBO 45MG BIDTICAGRELOR 45MG BID + PLACEBO 10MG BIDTotal
American Indian or Alaska Native0000
Asian0000
Native Hawaiian or Other Pacific Islander0000
Black or African American15141746
White15121340
More than one race0101
Unknown or Not Reported0000
08

Study locations

20 sites
  • Research Site
    Miami, Florida 33136, United States
  • Research Site
    Bethesda, Maryland 20817, United States
  • Research Site
    Charleston, South Carolina 29425, United States
  • Research Site
    Alexandria, 21131, Egypt
  • Research Site
    Cairo, 11562, Egypt
  • Research Site
    Cairo, 11566, Egypt
  • Research Site
    Bordeaux Cedex, 33076, France
  • Research Site
    Strasbourg, 67091, France
  • Research Site
    Verona, 37134, Italy
  • Research Site
    Kikuyu, 00100, Kenya
  • Research Site
    Kisian, 40100, Kenya
  • Research Site
    Nairobi, 40100, Kenya
  • Research Site
    Beirut, 1107 2020, Lebanon
  • Research Site
    Beirut, 113-6044, Lebanon
  • Research Site
    Adana, 01130, Turkey
  • Research Site
    Mersin, 33079, Turkey
  • Research Site
    Van, 65080, Turkey
  • Research Site
    Harrow, HA1 3UJ, United Kingdom
  • Research Site
    London, E1 1BB, United Kingdom
  • Research Site
    London, E9 6SR, United Kingdom
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2015 to primary completion in Nov 2016, 16 months.

Results were first posted in Dec 2017, 1 year after primary completion.

Of 34 industry-sponsored phase 2 interventional studies under Anemia, Sickle Cell, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 41. This study's 16 months is below that.

Counting every sponsor, half of 93 studies reached it within 46 months; a quarter within 24 and three quarters within 73.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 17, 2015
First posted
Jun 26, 2015
StartActual
Jul 9, 2015
Primary completionActual
Nov 16, 2016
CompletionActual
Nov 16, 2016
Results first posted
Dec 14, 2017
Last update
Dec 19, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 19, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02482298
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jun 26, 2015
Start date
Jul 9, 2015
Primary completion
Nov 16, 2016
Completion
Nov 16, 2016
Results posted
Dec 14, 2017
Last update
Dec 19, 2018

Study contacts

Maria Ignacia -Berraondo, MD
study director · Quintiles, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ticagrelor

Start the discussion